July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Glaucoma surveillance in patients receiving intravitreal injections in a regional eye clinic
Author Affiliations & Notes
  • Jie Cheng Song
    Ophthalmology, Sunshine Coast Hospital and Health Services, Caloundra, Queensland, Australia
  • Ee Lin Ong
    Ophthalmology, Sunshine Coast Hospital and Health Services, Caloundra, Queensland, Australia
  • Madeleine Adams
    Ophthalmology, Sunshine Coast Hospital and Health Services, Caloundra, Queensland, Australia
  • Footnotes
    Commercial Relationships   Jie Song, None; Ee Ong, None; Madeleine Adams, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6163. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jie Cheng Song, Ee Lin Ong, Madeleine Adams; Glaucoma surveillance in patients receiving intravitreal injections in a regional eye clinic. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6163. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients who receive IVI have an acute rise in intraocular pressure due to volume expansion. There is currently no evidence on the recommended frequencies for IOP monitoring and glaucoma surveillance in patients who are receiving regular intravitreal injections. To describe the awareness and methods used to monitor glaucoma development or progression in patients receiving intravitreal injection (IVI) in a regional eye clinic in Australia.

Methods : Retrospective audit was conducted of patients receiving IVI over a 3 week period in a regional eye clinic in Queensland, Australia. Data collected include sex, diabetes status, previous PRP/YAG treatment, indication for IVI, eye injected, glaucoma diagnosis, ocular hypertension (OHT) and glaucoma investigations performed within past 12 months.

Results : Preliminary results of 79 patients show majority of patients (53%) received IVI therapy for neovascular AMD, 23% for retinal vein occlusions, and 18% for diabetic macula edema. Only 11% have formal diagnosis of glaucoma. Of these, less than half (44%) had intervention post-IVI to alleviate the effect of IOP rise. Whilst all glaucoma patients received OCT RNFL in the past 12 months, less than half (30%) of IVI patients without glaucoma had these scans.

Conclusions : Glaucoma surveillance was performed in less than half of the patients in this audit. The outcomes highlight the need for increased awareness of glaucoma surveillance in this population of patients. Further research into the relationship between chronic IVI therapy and IOP changes with time will assist in identifying an optimal monitoring strategy for patients who are at higher risk of developing glaucoma.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×